Rugo HS, et al. - In women (aged ≥ 65 years) with HR+/HER2− advanced breast cancer (ABC) analyzed in randomized PALOMA clinical studies, researchers assessed outcomes with palbociclib plus endocrine therapy. In PALOMA-1 (open-label) and PALOMA-2 (double-blind, placebo-controlled), palbociclib plus letrozole or letrozole alone was administered to treatment-naïve patients. In PALOMA-3 (double-blind, placebo-controlled), palbociclib plus fulvestrant or fulvestrant alone was administered to patients with endocrine-resistant disease. Based on the findings, palbociclib plus endocrine therapy was proved to be an effective, well-tolerated treatment for older patients with ABC.